Microvascular complications of diabetes: Strategies for managing retinopathy, nephropathy, and neuropathy

Postgraduate Medicine

Volumn 103, Issue 1, 1998, Pages 61-68

  Seaquist, Elizabeth R ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICONVULSIVE AGENT; CAPSAICIN; CARBAMAZEPINE; CISAPRIDE; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUDROCORTISONE; GABAPENTIN; GASTROINTESTINAL AGENT; LOSARTAN POTASSIUM; METOCLOPRAMIDE; MIDODRINE; PAPAVERINE; PHENTOLAMINE MESYLATE; PHENYTOIN; PROSTAGLANDIN E1; TRICYCLIC ANTIDEPRESSANT AGENT;

AUTONOMIC NEUROPATHY; BLOOD PRESSURE REGULATION; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; IMPOTENCE; INTRACAVERNOUS DRUG ADMINISTRATION; LASER COAGULATION; ORAL DRUG ADMINISTRATION; ORTHOSTATIC HYPOTENSION; PENIS PROSTHESIS; PRACTICE GUIDELINE; REVIEW; SCREENING TEST; TOPICAL DRUG ADMINISTRATION;

EID: 0031909717     PISSN: 00325481     EISSN: None     Source Type: Journal    
DOI: 10.3810/pgm.1998.01.273     Document Type: Review

References (12)

1. Harris MI. Summary. In: National Diabetes Data Group. Diabetes in America. 2d ed. Bethesda: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 1995:1-13; NIH publication No. 95-1468
2. Rubin RJ, Altman WM, Mendelson DN. Health care expenditures for people with diabetes mellitus, 1992. J Clin Endocrinol Metab 1994;78(4):809A-809F
3. Nathan DM. Long-term complications of diabetes mellitus. N Engl J Med 1993; 328(23):1676-85
4. Ross MA. Neuropathies associated with diabetes. Med Clin North Am 1993;77(1): 111-24
5. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329(14):977-86
6. Trevisan R, Viberti G. Genetic factors in the development of diabetic nephropathy. J Lab Clin Med 1995;126(4):342-9
7. American Diabetes Association. Diabetic nephropathy. Diabetes Care 1997; 20(Suppl 1):S24-7
8. Collaborative Study Group. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329(20): 1456-62 [Erratum, N Engl J Med 1993;330(2):152]
9. Ravid M, Savin H, Jutrin I, et al. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 1993;118(8):577-81
10. Capsaicin Study Group. Effect of treatment with capsaicin on daily activities of patients with painful diabetic neuropathy. Diabetes Care 1992;15(2):159-65
11. Caputo GM, Cavanagh PR, Ulbrecht JS, et al. Assessment and management of foot disease in patients with diabetes. N Engl J Med 1994;331(13):854-60
12. Midodrine Study Group. Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension: a randomized, doubleblind multicenter study. JAMA 1997; 277(13):1046-51